Myriad brings cancer tests to India; OPKO finalizes $1.47B Bio-Reference Laboratories deal;

> Myriad Genetics ($MYGN) is partnering with India's Positive Bioscience to bring its molecular genomic tests for cancer to the country. Story

> Miami, FL-based OPKO Health sealed its $1.47 billion deal for sequencing company Bio-Reference Laboratories. Statement

> RainDance Technologies shimmied away from an IPO, deciding to withdraw plans to go public due to "market conditions." More

> Vermillion ($VRML) snagged CareFirst Blue Cross/Blue Shield coverage for its OVA1 ovarian cancer test. Statement

And Finally… Cambridge, MA-based Exosome Diagnostics is charging ahead with development of its liquid biopsy tests for lung cancer, planning to launch the products later this year. Story

Suggested Articles

Millions of tests are urgently needed as the virus keeps communities across the country in lockdown and hospitals are overwhelmed with patients.

The FDA granted its first emergency authorization for a rapid antibody blood test for COVID-19 developed by Cellex.

The ultimate goal is to move as many patients as possible out of the clinic that don’t need immediate, critical care.